Ocular Therapeutix Reports Presentation of Added Data from Most Recent Phase 3 Study Evaluating Safety, Efficacy of DEXTENZA 0.4 mg for Treatment of Ocular Pain, Inflammation Following Cataract Surgery
Paul Quintaro